Cell Therapy for Peripheral Artery Disease

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2018 Feb 18

PMID 29452987

Citations 21

Authors

Nikolaos G Frangogiannis

Affiliations

Soon will be listed here.

Abstract

Patients with severe peripheral artery disease (PAD) who are not candidates for revascularization have poor prognosis. Cell therapy using peripheral blood-derived or bone marrow-derived mononuclear cells, mesenchymal stem cells, or marker-specific subsets of bone marrow cells with angiogenic properties may hold promise for no-option PAD patients. Injected cells may exert beneficial actions by enhancing local angiogenesis (either through maturation of endothelial progenitors, or through secretion of angiogenic mediators), or by transducing cytoprotective signals that preserve tissue structure. Despite extensive research, robust clinical evidence supporting the use of cell therapy in patients with critical limb ischemia is lacking. Larger, well-designed placebo-controlled clinical trials did not support the positive results of smaller less rigorous studies. There is a need for high-quality clinical studies to test the effectiveness of cell therapy in PAD patients. Moreover, fundamental cell biological studies are needed to identify the optimal cell types, and to develop strategies that may enhance homing, survival and effectiveness of the injected cells.

Citing Articles

Growth factor free, peptide-functionalized gelatin hydrogel promotes arteriogenesis and attenuates tissue damage in a murine model of critical limb ischemia.

Curry C, Sturgeon S, OGrady B, Yates A, Kjar A, Paige H Biomaterials. 2023; 303:122397.

PMID: 37979513 PMC: 10843678. DOI: 10.1016/j.biomaterials.2023.122397.

The quality and quantity media-cultured mononuclear cell transplantation is safe and effective in ischemic hindlimb mouse model.

Chinchalongporn W, Chruewkamlow N, Sermsathanasawadi N, Vorateera K, Jintaworn S, Wongwanit C JVS Vasc Sci. 2023; 4:100129.

PMID: 37953747 PMC: 10632110. DOI: 10.1016/j.jvssci.2023.100129.

Target and Cell Therapy for Atherosclerosis and CVD.

Markina Y, Kirichenko T, Tolstik T, Bogatyreva A, Zotova U, Cherednichenko V Int J Mol Sci. 2023; 24(12).

PMID: 37373454 PMC: 10299192. DOI: 10.3390/ijms241210308.

Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review.

Arabzadeh A, Faghfuri E, Soofiyani S, Abdolahinia E, Siapush S, Nejati-Koshki K Adv Pharm Bull. 2023; 13(2):259-268.

PMID: 37342373 PMC: 10278215. DOI: 10.34172/apb.2023.025.

Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease.

Chen X, Yu W, Zhang J, Fan X, Liu X, Liu Q J Biol Eng. 2023; 17(1):13.

PMID: 36797776 PMC: 9936669. DOI: 10.1186/s13036-023-00330-2.

References

Huang P, Li S, Han M, Xiao Z, Yang R, Han Z . Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005; 28(9):2155-60. DOI: 10.2337/diacare.28.9.2155. View

Kundu N, Domingues C, Chou C, Ahmadi N, Houston S, Jerry D . Use of p53-Silenced Endothelial Progenitor Cells to Treat Ischemia in Diabetic Peripheral Vascular Disease. J Am Heart Assoc. 2017; 6(4). PMC: 5533015. DOI: 10.1161/JAHA.116.005146. View

Yoon C, Hur J, Park K, Kim J, Lee C, Oh I . Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005; 112(11):1618-27. DOI: 10.1161/CIRCULATIONAHA.104.503433. View

He L, Huang X, Kanisicak O, Li Y, Wang Y, Li Y . Preexisting endothelial cells mediate cardiac neovascularization after injury. J Clin Invest. 2017; 127(8):2968-2981. PMC: 5531398. DOI: 10.1172/JCI93868. View

Mathiyalagan P, Liang Y, Kim D, Misener S, Thorne T, Kamide C . Angiogenic Mechanisms of Human CD34 Stem Cell Exosomes in the Repair of Ischemic Hindlimb. Circ Res. 2017; 120(9):1466-1476. PMC: 5420547. DOI: 10.1161/CIRCRESAHA.116.310557. View

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T . Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-7. DOI: 10.1126/science.275.5302.964. View

Perin E, Murphy M, March K, Bolli R, Loughran J, Yang P . Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation. 2017; 135(15):1417-1428. PMC: 5388585. DOI: 10.1161/CIRCULATIONAHA.116.025707. View

Aicher A, Rentsch M, Sasaki K, Ellwart J, Fandrich F, Siebert R . Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res. 2007; 100(4):581-9. DOI: 10.1161/01.RES.0000259562.63718.35. View

Peeters Weem S, Teraa M, den Ruijter H, de Borst G, Verhaar M, Moll F . Quality of Life After Treatment with Autologous Bone Marrow Derived Cells in No Option Severe Limb Ischemia. Eur J Vasc Endovasc Surg. 2015; 51(1):83-9. DOI: 10.1016/j.ejvs.2015.09.010. View

10.

Iafrati M, Hallett J, Geils G, Pearl G, Lumsden A, Peden E . Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg. 2011; 54(6):1650-8. DOI: 10.1016/j.jvs.2011.06.118. View

11.

Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K . Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360(9331):427-35. DOI: 10.1016/S0140-6736(02)09670-8. View

12.

Powell R, Marston W, Berceli S, Guzman R, Henry T, Longcore A . Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012; 20(6):1280-6. PMC: 3369291. DOI: 10.1038/mt.2012.52. View

13.

Li M, Zhou H, Jin X, Wang M, Zhang S, Xu L . Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: preliminary clinical results. Exp Clin Transplant. 2013; 11(5):435-9. DOI: 10.6002/ect.2012.0129. View

14.

McDermott M . Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. Circ Res. 2015; 116(9):1540-50. PMC: 4410164. DOI: 10.1161/CIRCRESAHA.114.303517. View

15.

Losordo D, Kibbe M, Mendelsohn F, Marston W, Driver V, Sharafuddin M . A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012; 5(6):821-30. PMC: 3549397. DOI: 10.1161/CIRCINTERVENTIONS.112.968321. View

16.

Skora J, Pupka A, Janczak D, Barc P, Dawiskiba T, Korta K . Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia. Arch Med Sci. 2015; 11(2):325-31. PMC: 4424239. DOI: 10.5114/aoms.2013.39935. View

17.

Fowkes F, Rudan D, Rudan I, Aboyans V, Denenberg J, McDermott M . Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901):1329-40. DOI: 10.1016/S0140-6736(13)61249-0. View

18.

Frangogiannis N . Stromal cell-derived factor-1-mediated angiogenesis for peripheral arterial disease: ready for prime time?. Circulation. 2011; 123(12):1267-9. DOI: 10.1161/CIRCULATIONAHA.111.021204. View

19.

Ha D, Carpenter L, Koutakis P, Swanson S, Zhu Z, Hanna M . Transforming growth factor-beta 1 produced by vascular smooth muscle cells predicts fibrosis in the gastrocnemius of patients with peripheral artery disease. J Transl Med. 2016; 14:39. PMC: 4743093. DOI: 10.1186/s12967-016-0790-3. View

20.

Hristov M, Zernecke A, Liehn E, Weber C . Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost. 2007; 98(2):274-7. View